378 related articles for article (PubMed ID: 22975639)
1. Alu-based cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer.
Qi J; Qian C; Shi W; Wu X; Jing R; Zhang L; Wang Z; Ju S
Clin Biochem; 2013 Jan; 46(1-2):64-9. PubMed ID: 22975639
[TBL] [Abstract][Full Text] [Related]
2. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
[TBL] [Abstract][Full Text] [Related]
3. [Usefulness of preoperative assay CEA and CA 19-9 in colorectal cancer patients].
Grotowski M; Maruszyński M; Piechota W
Pol Merkur Lekarski; 2001 Dec; 11(66):476-9. PubMed ID: 11899841
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic value of serum carcino-embryonic antigen, alpha fetoprotein and carbohydrate antigen 19-9 for colorectal cancer.
Wang YR; Yan JX; Wang LN
J Cancer Res Ther; 2014 Dec; 10 Suppl():307-9. PubMed ID: 25693941
[TBL] [Abstract][Full Text] [Related]
5. Serum sAPRIL: a potential tumor-associated biomarker to colorectal cancer.
Ding W; Wang J; Wang F; Wang G; Wu Q; Ju S; Cong H; Wang H
Clin Biochem; 2013 Oct; 46(15):1590-4. PubMed ID: 23792260
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of serum CEA, CA19-9 and CA125 in diagnosis of colorectal liver metastasis in Chinese population.
Zhang D; Yu M; Xu T; Xiong B
Hepatogastroenterology; 2013 Sep; 60(126):1297-301. PubMed ID: 23933921
[TBL] [Abstract][Full Text] [Related]
7. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
8. Estimating the probability of cancer with several tumor markers in patients with colorectal disease.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Oncology; 2004; 66(4):296-302. PubMed ID: 15218297
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of circulating galectins as colorectal cancer markers.
Watanabe M; Takemasa I; Kaneko N; Yokoyama Y; Matsuo E; Iwasa S; Mori M; Matsuura N; Monden M; Nishimura O
Oncol Rep; 2011 May; 25(5):1217-26. PubMed ID: 21369702
[TBL] [Abstract][Full Text] [Related]
10. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer.
Flamini E; Mercatali L; Nanni O; Calistri D; Nunziatini R; Zoli W; Rosetti P; Gardini N; Lattuneddu A; Verdecchia GM; Amadori D
Clin Cancer Res; 2006 Dec; 12(23):6985-8. PubMed ID: 17145818
[TBL] [Abstract][Full Text] [Related]
11. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
12. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
Zhao XW; Jiang B; Han CZ; Jing JX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma.
Zhang SY; Lin M; Zhang HB
Int J Clin Exp Pathol; 2015; 8(8):9404-9. PubMed ID: 26464695
[TBL] [Abstract][Full Text] [Related]
14. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of tumor markers and evaluation of their predictive value in patients with colorectal cancer.
Liu ZP; Li LM; Liu XL; Zhang DX
Onkologie; 2012; 35(3):108-13. PubMed ID: 22414974
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin serum biomarkers in patients with colorectal cancer.
Holdenrieder S; Stieber P; Liska V; Treska V; Topolcan O; Dreslerova J; Matejka VM; Finek J; Holubec L
Anticancer Res; 2012 May; 32(5):1971-6. PubMed ID: 22593474
[TBL] [Abstract][Full Text] [Related]
17. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
[TBL] [Abstract][Full Text] [Related]
18. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
19. Circulating midkine in malignant and non-malignant colorectal diseases.
Krzystek-Korpacka M; Diakowska D; Neubauer K; Gamian A
Cytokine; 2013 Oct; 64(1):158-64. PubMed ID: 23899719
[TBL] [Abstract][Full Text] [Related]
20. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
